<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00337506</url>
  </required_header>
  <id_info>
    <org_study_id>BRD 03/6-E</org_study_id>
    <nct_id>NCT00337506</nct_id>
  </id_info>
  <brief_title>Velcade Combined With High-Dose Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma</brief_title>
  <official_title>A Multicenter Open-Label Phase II Study of Velcade Combined With High-Dose Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nantes University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nantes University Hospital</source>
  <brief_summary>
    <textblock>
      The objective of this study is to evaluate the efficacy and safety of Velcade plus
      dexamethasone used as induction chemotherapy prior to autologous transplantation.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <start_date>August 2003</start_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Complete remission after 4 cycles:</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>disappearance of serum and/or urine M-component (confirmed by immunofixation)</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>&lt; 5% plasma cells in the bone marrow resolution of all extra-osseous plasmacytomas</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>no evidence of bone progression</measure>
  </primary_outcome>
  <enrollment>50</enrollment>
  <condition>Multiple Myeloma</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>velcade</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  diagnosis of MM according to the SWOG criteria (annex 1)

          -  previously untreated (localized radiotherapy is allowed)

          -  symptomatic MM stage II or III according to Durie-Salmon staging system (annex 2) or
             stage I with one symptomatic osteolytic lesion

          -  with measurable levels of paraprotein in the serum (&gt; 1g/dl) or in the urine (&gt;
             0.2g/24h)

          -  age &lt; 75 years

          -  able to understand and to given an informed consent

          -  male, female without childbearing potential or negative urine pregnancy test within 72
             hours prior to beginning the treatment. Women of childbearing potential must be
             following adequate contraceptive measures.

          -  no active systemic infection. In the presence of any active systemic infection,
             adequate broad-spectrum or organism-specific antibiotic coverage must be administered.
             Patients must be a febrile with stable vital signs while receiving antibiotics for at
             least 48 hours prior to beginning the treatment with Velcade plus dexamethasone.

        Exclusion Criteria:

          -  life expectancy &lt; 2 months

          -  ECOG performance status &gt; 2 (annex 3)

          -  proven amyloidosis

          -  positive HIV serology

          -  antecedents of severe psychiatric disease

          -  severe diabetes contraindicating the use of high-dose cortico√Øds

          -  &gt; NCI grade 2 peripheral neuropathy (Annex IV)

          -  serum biochemical values as follow

               -  creatinin level &gt; 200mmol/l

               -  bilirubin, transaminases or gGT &gt; 3 the upper normal limit

          -  use of any experimental drugs within 30 days of baseline
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jean-Luc HAROUSSEAU, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>NANTES UH</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Jean-Luc HAROUSSEAU</name>
      <address>
        <city>Nantes</city>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>August 2004</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 14, 2006</study_first_submitted>
  <study_first_submitted_qc>June 15, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 16, 2006</study_first_posted>
  <last_update_submitted>June 15, 2006</last_update_submitted>
  <last_update_submitted_qc>June 15, 2006</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 16, 2006</last_update_posted>
  <keyword>the efficacy and safety of Velcade plus dexamethasone</keyword>
  <keyword>Multiple Myeloma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Bortezomib</mesh_term>
    <mesh_term>BB 1101</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

